Letter: Trajectories of Hepatic Function Markers Enable Early Prediction of Hepatic Recompensation

作者：Benedikt Hofer, Jan Embacher, Georg Semmler, Thomas Reiberger · 发表于：Alimentary Pharmacology & Therapeutics · 年份：2026 · DOI：10.1111/apt.70521 · 被引用次数：2 · 研究领域：Liver Disease and Transplantation、Liver Disease Diagnosis and Treatment、Drug-Induced Hepatotoxicity and Protection

Hepatic recompensation has emerged as a distinct stage of cirrhosis [1], supporting the concept of disease regression even in the stage of decompensated cirrhosis once the underlying aetiological driver is controlled or removed [2]. Although previous studies have consistently demonstrated improved outcomes following recompensation [3-6], baseline predictors of a patient's recompensation likelihood vary across cohorts, aetiologies, and clinical scenarios. Although liver disease severity has consistently been identified as a key determinant of recompensation [3-5], the predictive value of hepatic function markers appears context-dependent. For instance, while lower MELD robustly predicted recompensation in clinically stable patients [3, 5], higher MELD was linked to increased recompensation rates in patients with ongoing hepatic necroinflammation due to viral hepatitis [6]. Xia et al. [7] now provide insights into recompensation in decompensated hepatitis B virus (HBV) cirrhosis, reporting a recompensation rate of 78% and providing data on the context-specific role of laboratory markers of hepatic function and portal hypertension. They also introduce the term ‘unstable recompensation’ to describe patients who either experienced another decompensating event after recompensation or achieved recompensation only after multiple decompensating events. The ‘unstable recompensated’ patients comprised 31% of the recompensated cohort and had an intermediate prognosis compared to those wi...